Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2004-05-28
2010-10-05
Johannsen, Diana B (Department: 1634)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S091200, C536S025320, C514S283000
Reexamination Certificate
active
07807350
ABSTRACT:
The present invention concerns the methods and compositions for evaluating the risk of ironotecan toxicity in a cancer patient based on the genotype of the patient at position −3156 of the UGT1A1 gene or at any position in linkage disequilibrium with the −3156 variant.
REFERENCES:
patent: 5786344 (1998-07-01), Ratain et al.
patent: 5972614 (1999-10-01), Ruano et al.
patent: 6066645 (2000-05-01), Hausheer et al.
patent: 6287834 (2001-09-01), Belanger et al.
patent: 6319678 (2001-11-01), Trubetskoy et al.
patent: 6395481 (2002-05-01), Di Rienzo et al.
patent: 6407117 (2002-06-01), Bouscarel et al.
patent: 6448003 (2002-09-01), Guida et al.
patent: 6472157 (2002-10-01), Di Rienzo et al.
patent: 6479236 (2002-11-01), Penny et al.
patent: 6586175 (2003-07-01), Galvin et al.
patent: 2002/0061518 (2002-05-01), Penny et al.
patent: 2003/0077629 (2003-04-01), Galvin et al.
patent: 2003/0099960 (2003-05-01), Ratain et al.
patent: 2003/0099977 (2003-05-01), Guida et al.
patent: 2003/0157517 (2003-08-01), Penny et al.
patent: 2004/0058363 (2004-03-01), Hasegawa et al.
patent: 2004/0076968 (2004-04-01), Acuna et al.
patent: 2004/0121327 (2004-06-01), Manns et al.
patent: 2004/0203034 (2004-10-01), Ratain et al.
patent: 0919244 (1999-06-01), None
patent: 1352970 (2003-10-01), None
patent: 2004-073035 (2004-03-01), None
patent: WO 94/22846 (1994-10-01), None
patent: WO 95/08986 (1995-04-01), None
patent: WO 96/01127 (1996-01-01), None
patent: WO 97/32042 (1997-09-01), None
patent: WO 99/57322 (1999-11-01), None
patent: WO 00/06776 (2000-02-01), None
patent: WO 01/79230 (2001-10-01), None
patent: WO 02/06523 (2002-01-01), None
patent: WO 02/053770 (2002-07-01), None
patent: WO 02/057410 (2002-07-01), None
patent: WO 03/013536 (2003-02-01), None
patent: WO 03/013537 (2003-02-01), None
patent: WO 2004/016814 (2004-02-01), None
Ruano, G. et al. Nucleic Acids Research 19(24):6877-6882 (1991).
Abraham et al., “Non-glucocorticoid steriod analogues (21-aminosteroids) sensitize multidrug resistant cells to vinblastine,”Cancer Chemother. Pharmacol., 32(2):116-122, 1993.
Akiyama et al., “Most drugs that reverse multidrug resistance also inhibit photoaffinity labeling of p-glycoprotein by a vinblastine analog,”Mol. Pharmacol., 33(2):144-147, 1988.
Ando et al., “Polymorphisms of UDP-Glucuronsyltransferase Gene and Irinotecan Toxicity: A Pharmacogenetic Analysis,”Cancer Res., 60(24):6921-6926, 2000.
Ando et al., “UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan,”Annals of Oncology, 9:845-847, 1998.
Ansher et al., “Chemoprotective effects of two dithiolthiones and of butylhydroxyanisole against carbon tetrachloride and acetaminophen toxicity,”Hepatology, 3(6):932-935, 1983.
Araki et al., “Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and blood plasma of athymic mice following intraperitoneal administration of CPT-11,”Jpn J. Cancer Res., 84:697-702, 1993.
Ariyoshi et al., “Mouse-human chimeric antibody MH171 against the multidrug transporter P-glycoprotein,”Jpn. J. Cancer Res., 83(5):515-521, 1992.
Atsumi et al., “Identification of the Metabolites of Irinotecan, a New Derivative of Camptothecin, in Rat Bile and its Biliary Excretion,”Xenobiotica, 21(9):1159-1169, 1991.
Barbier et al., “3′-azido-3′-deoxythimidine (AZT) is glucuronidated by human UDP-glucuronosyltransferase 3B7 (UGT2B7),”Drug Metab. Dispos., 28:497-502, 2000.
Barker et al., “Determination of plasma concentrations of epirubicin and its metabolites by high-performance liquid chromatography during a 96-h infusion in cancer chemotherapy,”J Chromatogr B Biomed Appl, 681:323-329, 1996.
Bear, “Drugs transported by-P-glycoprotein inhibit a 40pS outwardly rectifying chloride channel,”Biochem. Biophys. Res. Commun., 200(1):513-521, 1994.
Bell et al., “Roles of peptidyl-prolyl cis-trans isomerase and calcineurin in the mechanisms of antimalarial action of cyclosporin A, FK506, and rapamycin,”Biochem. Pharmacol., 48(3):495-503, 1994.
Bertrand et al.., “Sequential Administration of Camptothecin and Etoposide Circumvents the Antagonistic Cytotoxicity of Simultaneous Drug Administration in Slowly Growing Human Colon Carcinoma HT-29 Cells,”Eur. J. Cancer, 28A(4-5):743-748, 1992.
Beutler et al., “Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism,”PNAS USA, 95:8170-8174, 1998.
Bhasker et al., “Genetic polymorphism of UDP-glucuronosyltransferase 2B7 (UGT2B7) at amino acid 268: ethnic diversity of alleles and potential clinical significance,”Pharmacogenetics, 10(8):679-685, 2000.
Bible and Kaufmann, “Cytotoxic synergy between flavopiridol (NSSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration,”Cancer Res., 57:3375-3380, 1997.
Bible and Kaufmann, “Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells,”Cancer Res., 56:4856-4861, 1996.
Bock et al., “Purification of Rat Liver UDP-Glucuaronyltransferase: Separation of Two Enzyme Forms with Different Substrate Specificity and Differential Inducibility,” In: Conjugation reactions in biotransformation, Elsevier, North Holland Biomedical Press, p. 357-364, 1978.
Boesch and Loor, “Extent and persistence of P-glycoprotein inhibition in multidrug-resistant P388 cells after exposure to resistance-modifying agents,”Anticancer Drugs, 5(2):229-238, 1994.
Boesch et al., “Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative,”Exp. Cell. Res., 196(1):26-32, 1991.
Boiteux-Antoine et al., “Comparative induction of drug-metabolizing enzymes by hypolipidaemic compounds,”Gen-Pharmacol, 20(4):407-412, 1989.
Bosma et al., “Sequence of exons and the flanking regions of human bilirubin-UDP-glucuronosyltransferase gene complex and identification of a genetic mutation in a patient with Crigler-Najjar Syndrome, Type I,”Hepatology, 15:941-947, 1992.
Bosma et al., “The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome,”New England Journal of Medicine, 333:1171-1175, 1995.
Burchell and Coughtrie, “UDP-glucuronosyltransferases,”Pharmac. Ther., 43:261-289, 1989.
Burchell et al., “The UDP Glucuronosyltransferase gene suprefamily: suggested nomenclature based on evolutionary divergence,”DNA Cell Biol., 10:487-494, 1991.
Burger et al., “Pharmacokinetic interaction between rifampin and zidovudine,”Antimicrobial Agents and Chemotherapy, 37(7):1426-1431, 1993.
Campain et al., “Characterization of an unusual mutant of human melanoma cells resistant to anticancer drugs that inhibit topoisomerase II,”J. Cell Physiol., 155(2):414-425, 1993.
Carlson et al., “Flavopiridol induces G1arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells,”Cancer Res, 56:2973-2978, 1996.
Carrier et al., “Isolation and characterization of the human UGT2B7 gene,”Biochem and Biophys. Res. Commun., 272:616-621, 2000.
Cascorbi et al., “Frequency of single nucleotide polymorphisms in the p-glycoprotein drug transporter MDR1 gene in white subjects,”Clinc. Pharmacol Ther., 69:169-174, 2001.
Charuk et al., “Interaction of Rat Kidney P-Glycoprotein with a Urinary Component and Various Drugs Including Cyclosporin A,”Am. J. Physiol., 266:F66-F75, 1994.
Chen and Okayama, “Calcium phosphate-mediated gene transfer: A highly efficient transfection system for stably transforming cells with plasmid DNA,”Biotechniques, 6:632-638,
Di Rienzo Anna
Grimsley Carrie
Innocenti Federico
Ratain Mark J.
Fulbright & Jaworski L.L.P.
Johannsen Diana B
The University of Chicago
LandOfFree
Methods for predicting irinotecan toxicity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for predicting irinotecan toxicity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for predicting irinotecan toxicity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4231237